Sutro Biopharma

GPTKB entity

Statements (65)
Predicate Object
gptkbp:instance_of gptkb:biotechnology
gptkbp:acquisition gptkb:Sutro_Biopharma,_Inc.
gptkbp:business_model biopharmaceutical development
partnerships with pharma companies
gptkbp:ceo gptkb:Bill_Newell
gptkbp:clinical_trial gptkb:pharmaceuticals
gptkb:cancer_treatment
Phase 1
Phase 2
Phase 3
autoimmune diseases
ongoing studies
cancer therapies
published results
autoimmune treatment
gptkbp:collaboration academic institutions
pharmaceutical companies
gptkbp:collaborations universities
research organizations
gptkbp:community_engagement gptkb:healthcare_professionals
patient advocacy groups
gptkbp:employees over 100
gptkbp:focus therapeutics
gptkbp:founded gptkb:2003
gptkbp:founder gptkb:Bill_Newell
gptkbp:funding public offerings
private placements
gptkbp:future_plans enhance technology platform
expand pipeline
increase collaborations
gptkbp:headquarters gptkb:South_San_Francisco,_California
https://www.w3.org/2000/01/rdf-schema#label Sutro Biopharma
gptkbp:instruction_set multiple drug candidates
gptkbp:investment Venture capital
institutional investors
venture capital firms
gptkbp:is_a_platform_for gptkb:Xpress_CF+_technology
Xpress CF technology
gptkbp:lead_candidate STRO-002
STRO-001
STRO-003
gptkbp:leadership experienced management team
scientific advisors
gptkbp:market oncology
immunology
gptkbp:marketing_strategy targeted therapies
precision medicine
gptkbp:partnership gptkb:Bristol-Myers_Squibb
gptkb:Celgene
gptkbp:partnerships research institutions
biotech firms
gptkbp:publications peer-reviewed journals
gptkbp:regulatory_compliance gptkb:FDA
gptkb:EMA
gptkbp:research_and_development biopharmaceuticals
gptkbp:research_focus biologics
antibody-drug conjugates
gptkbp:specialization protein engineering
gptkbp:stock_exchange gptkb:NASDAQ
gptkbp:technology Xpress CF
Xpress CF+ platform
gptkbp:trade STRO
gptkbp:website www.sutrobio.com
gptkbp:bfsParent gptkb:Ariad_Pharmaceuticals
gptkbp:bfsLayer 5